Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL112713 | 0.81 | YTHDC1 (0.62) | YTHDC1CYP2C19RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL117130 | 0.80 | PIK3CA (0.52) | YTHDC1RAB9ASMN1; SMN2NPC1FLT3 | |
| SCHEMBL753502 | 0.79 | YTHDC1 (0.47) | YTHDC1CYP2C19RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL114675 | 0.78 | YTHDC1 (0.50) | YTHDC1CYP2C19RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL115435 | 0.77 | YTHDC1 (0.49) | YTHDC1CYP2C19RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL114895 | 0.77 | YTHDC1 (0.46) | YTHDC1CYP2C19RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL29878036 | 0.77 | YTHDC1 (0.46) | YTHDC1CYP2C19RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL13798746 | 0.75 | YTHDC1 (0.59) | YTHDC1CYP2C19RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL31186403 | 0.74 | YTHDC1 (0.47) | YTHDC1CYP2C19RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL115879 | 0.74 | CYP2C19 (0.45) | YTHDC1CYP2C19RAB9ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424859-B1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8772480-B2 | Inhibitors of PI3 kinase and/or mTOR | AMGEN INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | AMGEN INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-8362241-B2 | Inhibitors of PI3 kinase and/or mTOR | AMGEN INC. (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2424859-A1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | Amgen, Inc (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126895-A1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | AMGEN INC. (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | MTOR, PIK3CA, PIK3CD | YTHDC1 4746/4885CYP2C19 1960/4885RAB9A 545/4885 |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | MTOR, PIK3CA, PIK3CD | YTHDC1 4746/4885CYP2C19 1960/4885RAB9A 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.